{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:14:53Z","timestamp":1783556093451,"version":"3.55.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,8]]},"DOI":"10.1093\/oncolo\/oyag251","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T16:50:56Z","timestamp":1782751856000},"source":"Crossref","is-referenced-by-count":0,"title":["Modernizing disease assessment in prostate cancer trials: the Prostate Cancer Working Group 4 framework"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2181-8405","authenticated-orcid":false,"given":"Miguel","family":"Zugman","sequence":"first","affiliation":[{"name":"Centro de Oncologia e Hematologia Einstein Fam\u00edlia Dayan\u2014Daycoval, Hospital Israelita Albert Einstein , S\u00e3o Paulo, SP, 05652-900,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8890-2951","authenticated-orcid":false,"given":"Pedro C","family":"Barata","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, Department of Medicine, University Hospitals Cleveland Medical Center , Cleveland, OH, 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"2026070819212974400_oyag251-B1","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026070819212974400_oyag251-B2","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026070819212974400_oyag251-B3","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1200\/JCO-25-01693","article-title":"National cancer institute\u2019s working group on biochemically recurrent prostate cancer: clinical trial design considerations","volume":"43","author":"Einstein","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026070819212974400_oyag251-B4","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/s41591-024-02827-9","article-title":"Recommendations to address respondent burden associated with patient-reported outcome assessment","volume":"30","author":"Aiyegbusi","year":"2024","journal-title":"Nat Med"},{"key":"2026070819212974400_oyag251-B5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1001\/jamaoncol.2019.4636","article-title":"Association between new unconfirmed bone lesions and outcomes in men with metastatic castration-resistant prostate cancer treated with enzalutamide: secondary analysis of the PREVAIL and AFFIRM randomized clinical trials","volume":"6","author":"Armstrong","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026070819212974400_oyag251-B6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol"},{"key":"2026070819212974400_oyag251-B7","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1158\/1078-0432.CCR-24-1096","article-title":"Circulating tumor DNA assessment for treatment monitoring adds value to PSA in metastatic castration-resistant prostate cancer","volume":"30","author":"Sweeney","year":"2024","journal-title":"Clinical Cancer Research"},{"key":"2026070819212974400_oyag251-B8","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1200\/JCO.19.01479","article-title":"Ethical framework for including research biopsies in oncology clinical trials: American Society of Clinical Oncology research statement","volume":"37","author":"Levit","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026070819212974400_oyag251-B9","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","article-title":"The role of lineage plasticity in prostate cancer therapy resistance","volume":"25","author":"Beltran","year":"2019","journal-title":"Clinical Cancer Research"},{"key":"2026070819212974400_oyag251-B10","doi-asserted-by":"publisher","first-page":"11271","DOI":"10.1038\/s41598-024-61961-z","article-title":"Dual FDG\/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT","volume":"14","author":"Rosar","year":"2024","journal-title":"Sci Rep"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag251\/68645786\/oyag251.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/8\/oyag251\/68645786\/oyag251.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/8\/oyag251\/68645786\/oyag251.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T23:21:31Z","timestamp":1783552891000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag251\/8721586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag251","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,6,29]]},"article-number":"oyag251"}}